Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Updated
Over 1400 clinical trials and research studies were reviewed by a panel of 13 experts to develop the new guideline.
All articles by Diana Ernst, RPh
Does DPP-4 Inhibitor Use Increase the Risk of Developing IBD?
To investigate the association between this diabetes drug class and IBD risk, the study authors searched various databases for controlled clinical trials and observational studies involving DPP-4 inhibitors where IBD events were reported.
FDA Panel Votes on Novel Osteoporosis Treatment Evenity
In the Biologics License Application (BLA) resubmission, Amgen and UCB proposed to narrow the indication to treatment of osteoporosis in postmenopausal women at high risk of fracture.
FDA Committee Votes on Oral T1D Treatment Sotagliflozin
The FDA takes the advice of the panel into consideration when making decisions, however it is not bound by their recommendations.
Health Experts Review 41 Diets, Rank Best Overall for 2019
An expert panel assessed 41 diets to come up with their final results, examining the evidence behind each diet’s claims, the short-term and long-term weight loss associated with the diet, how easy the diet is to follow, how well each diet conforms to current nutrition standards, and its effect on diabetes and cardiovascular disease prevention.
SGLT2 Inhibitors and Urinary Tract Infections: What’s the Link?
For this study, the authors identified randomized controlled trials (RCTs) that compared SGLT2 inhibitors with placebo, no treatment, or another antidiabetic agent and reported on UTI outcome.
Menopausal Hormone Therapy May Reduce Carpal Tunnel Syndrome Risk
To investigate the association between hormone therapy and carpal tunnel syndrome risk, researchers conducted a secondary analysis of the Women’s Health Initiative (WHI) hormone therapy trials.
FDA to Review Estrogen-Free Oral Contraceptive Slinda
Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity.
Hypoglycemia Following Antifungal Treatment in Patient With Type 1 Diabetes
“This is the first report of decreased insulin requirements in a patient with [T1D] correlating with micafungin administration,” noted the authors.
Another Antihypertensive Recalled Due to Potentially Carcinogenic Impurity
The impurity was identified following laboratory testing conducted by the Food and Drug Administration (FDA); this is the first non-valsartan product that the Agency has found to contain NDEA.
Next post in Type 2 Diabetes
